Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$536.32M
EBITDA Margin
-17741.55%
TTM Avg
-126136.56%
3Y Avg
-126136.56%
5Y Avg
-126136.56%
Market Cap
$540.74M
EBITDA Margin
1.18%
TTM Avg
-15.78%
3Y Avg
-775.36%
5Y Avg
-845.24%
Market Cap
$542.04M
EBITDA Margin
-91.00%
TTM Avg
-295.88%
3Y Avg
-8346.66%
5Y Avg
-8346.66%
Market Cap
$523.17M
EBITDA Margin
-1406.75%
TTM Avg
-1406.75%
3Y Avg
-151851.64%
5Y Avg
-92301.39%
Market Cap
$520.33M
EBITDA Margin
-230187.80%
TTM Avg
-372428.90%
3Y Avg
-255754.79%
5Y Avg
-154022.75%
Market Cap
$516.21M
EBITDA Margin
-35.08%
TTM Avg
-77.94%
3Y Avg
-77.08%
5Y Avg
-62.83%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | $535.31M | N/A | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $536.32M | -17741.55% | -126136.56% | -126136.56% | -126136.56% |
| Delcath Systems, Inc. (DCTH)vs › | $540.74M | 1.18% | -15.78% | -775.36% | -845.24% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $542.04M | -91.00% | -295.88% | -8346.66% | -8346.66% |
| Crescent Biopharma, Inc. (CBIO)vs › | $523.17M | -1406.75% | -1406.75% | -151851.64% | -92301.39% |
| Monopar Therapeutics Inc. (MNPR)vs › | $521.25M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $520.33M | -230187.80% | -372428.90% | -255754.79% | -154022.75% |
| 908 Devices Inc. (MASS)vs › | $516.21M | -35.08% | -77.94% | -77.08% | -62.83% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $554.88M | N/A | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $554.42M | -970.11% | -861.99% | -583.02% | -735.09% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
